Search

Your search keyword '"Altintas, Ayse"' showing total 413 results

Search Constraints

Start Over You searched for: Author "Altintas, Ayse" Remove constraint Author: "Altintas, Ayse"
413 results on '"Altintas, Ayse"'

Search Results

51. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

52. Effects of the epiretinal membrane on the outcomes of intravitreal dexamethasone implantation for macular edema secondary to branch retinal vein occlusion

53. Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Real-Life Outcomes from a Multicenter Study in Turkey over 36 months

55. The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?

56. sj-docx-1-msj-10.1177_13524585221137502 – Supplemental material for Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

58. Effects of the epiretinal membrane on the outcomes of intravitreal dexamethasone implantation for macular edema secondary to branch retinal vein occlusion.

59. Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders

60. Retinal Optical Coherence Tomography in Neuromyelitis Optica

61. A 52-Year-Old Man With Progressive Weakness and Incontinence

62. 004 Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis

65. Assessment of brain atrophy and lesion burden with clinical outcomes in multiple sclerosis real-world practice: The NeuroSTREAM MSBase retrospective, longitudinal study

67. Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors

68. Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study.

69. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

71. Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)

72. Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis (2901)

73. Assessment of brain atrophy and lesion burden with clinical outcomes in multiple sclerosis real-world practice: The NeuroSTREAM MSBase retrospective, longitudinal study (2699)

77. Early clinical markers of aggressive multiple sclerosis.

78. Treatment response score to glatiramer acetate or interferon beta-1a.

79. Risk of secondary progressive multiple sclerosis: A longitudinal study.

82. Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study

83. The MSBase pregnancy, neonatal outcomes, and women’s health registry

84. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

87. Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.

92. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

94. Early clinical markers of aggressive multiple sclerosis

97. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

99. Sex effects across the lifespan in women with multiple sclerosis

Catalog

Books, media, physical & digital resources